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 Background Adult alcohol consumption during the previous year is related to breast cancer risk. Breast tissue is particularly 
susceptible to carcinogens between menarche and first full-term pregnancy. No study has characterized the con-
tribution of alcohol consumption during this interval to risks of proliferative benign breast disease (BBD) and 
breast cancer.
 Methods We used data from 91 005 parous women in the Nurses’ Health Study II who had no cancer history, completed 
questions on early alcohol consumption in 1989, and were followed through June 30, 2009, to analyze breast 
cancer risk. A subset of 60 093 women who had no history of BBD or cancer in 1991 and were followed through 
June 30, 2001, were included in the analysis of proliferative BBD. Relative risks (RRs) were estimated using Cox 
proportional hazard regression.
 Results We identified 1609 breast cancer cases and 970 proliferative BBD cases confirmed by central histology review. 
Alcohol consumption between menarche and first pregnancy, adjusted for drinking after first pregnancy, was 
associated with risks of breast cancer (RR = 1.11 per 10 g/day intake; 95% confidence interval [CI] = 1.00 to 1.23) 
and proliferative BBD (RR = 1.16 per 10g/day intake; 95% CI = 1.02 to 1.32). Drinking after first pregnancy had a 
similar risk for breast cancer (RR = 1.09 per 10 g/day intake; 95% CI = 0.96 to 1.23) but not for BBD. The association 
between drinking before first pregnancy and breast neoplasia appeared to be stronger with longer menarche to 
first pregnancy intervals.
 Conclusions Alcohol consumption before first pregnancy was consistently associated with increased risks of proliferative BBD 
and breast cancer.
  J Natl Cancer Inst;2013;105:1571–1578 
Alcohol is considered by the International Agency for Research 
on Cancer to be causally related to invasive breast cancer (here-
after called “breast cancer”) (1), with a 7% to 10% increase in risk 
for each 10 g alcohol consumed daily by adult women (2–4). One 
mechanism may be alcohol-induced increases in circulating estro-
gens and subsequently epithelial cell proliferation (3). However, 
the risk attributable to alcohol intake during adolescence and early 
adulthood remains inconclusive (2,5–12).
Younger age at menarche and older age at first full-term preg-
nancy (hereafter called “pregnancy”) are associated with increased 
risk for breast cancer (13–15). Breast tissue undergoes rapid cellular 
proliferation between these reproductive events, and risk accumu-
lates most rapidly until the terminal differentiation that accompa-
nies first pregnancy. First pregnancy has both a short-term adverse 
effect on risk and a long-term reduction in subsequent risk accu-
mulation (16). The longer the interval between menarche and first 
pregnancy the greater is a woman’s breast cancer risk (14,15,17). 
Therefore, menarche to first pregnancy represents a window of 
time when breast tissue is particularly vulnerable to carcinogenic 
stimuli (18). Alcohol consumption in late adolescence and early 
adulthood is associated with increased risk of proliferative benign 
breast disease (BBD), a known risk marker for breast cancer (19,20).
We therefore hypothesized that alcohol consumed before 
first pregnancy is associated with risks of both proliferative BBD 
and breast cancer, independent of drinking after first pregnancy. 
Such an association may be stronger when the menarche to first 
pregnancy interval is longer.
Methods
The Nurses’ Health Study II (NHSII) was established in 1989 when 
116 671 female registered nurses aged 25 to 44  years completed 
a mailed questionnaire about their medical history, reproductive 
history, and lifestyles. Follow-up questionnaires mailed biennially 
updated information on lifestyles, reproductive factors, and medi-
cal events. The overall response rate to each questionnaire through 
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2003 was 90% (20). NHSII participants provided implied consent 
with return of biennial questionnaires. This study was approved by 
the Human Subjects Committees at the Harvard School of Public 
Health and Brigham and Women’s Hospital.
Alcohol Consumption
Participants were asked in 1989 about their alcohol consumption 
in four age periods (ages 15–17, 18–22, 23–30, and 31–40 years). 
Participants were asked about the total number of drinks of alco-
hol (including beer, wine, and liquor together) consumed at differ-
ent ages, with nine response categories ranging from “none or <1/
month” to “40+/week.” One drink was defined as one bottle/can 
of beer, a 4-ounce glass of wine, or a shot of liquor. The estimated 
content of ethanol per alcoholic drink was 12.0 g (19).
Alcohol consumption over the previous year was asked sepa-
rately for beer, for wine, and for liquor in the nine categories rang-
ing from “none or <1/month” to “40+/week.” Total amounts of 
alcohol consumed in the previous year were calculated based on the 
equivalents of 12.8 g for regular beer, 11.0 g for wine, and 14.0 g for 
liquor (19). Current drinking was updated in 1991, 1995, 1999, and 
2003. During the follow-up, participants were asked about their 
alcohol consumption separately for regular and light beer, red and 
white wine, and liquor. The estimated ethanol content of a serving 
of light beer was 11.3 g (21).
Cumulative average alcohol intake, a measure of intensity of 
drinking, between menarche and first pregnancy (of ≥6  months 
gestation) was calculated by multiplying drinking (grams per day) 
in each individual age period before first pregnancy by the length 
of the corresponding period, summing the contributions from each 
age period, and dividing by the interval length (years). For example, 
for a woman who had menarche at age 15 years and first pregnancy 
at age 25 years, cumulative drinking was obtained by summing alco-
hol consumed at three different ages (ages 15–17 years, 18–22 years, 
and 23–30 years) that were separately adjusted for the proportions 
of the corresponding individual age periods in her total menarche to 
first pregnancy duration of 10 years. Because alcohol consumption 
before age 15 years was not collected, cumulative drinking from age 
15 onward was calculated if menarche occurred before age 15 years.
We also calculated cumulative average alcohol consumption 
between first pregnancy and menopause (or current age for pre-
menopausal women) in a similar manner to examine whether the 
association with alcohol consumption before first pregnancy is 
independent of drinking after first pregnancy. Similarly, estimates 
of cumulative average drinking after first pregnancy were updated 
during the follow-up until menopause.
Study Sample for Analysis
Among 116 671 participants in the original cohort, 3929 were 
excluded because of lack of data on age at menarche, parity, age 
at first pregnancy, or alcohol consumption at baseline and during 
four age periods―the variables that were used to estimate cumu-
lative drinking between menarche and first pregnancy. We also 
excluded women who developed cancer before 1989 (n = 1004) 
and women who had never carried a pregnancy achieving at 
least 6 months of gestation at baseline and during the follow-up 
(n = 20 733), leaving 91 005 participants included in the analysis 
of breast cancer risk.
Because biopsy specimens were reviewed for women who 
reported a first diagnosis of biopsy-confirmed BBD during the pre-
vious 2 years on the 1993 to 2001 questionnaires, the analytic period 
for proliferative BBD was from 1991 to 2001. Among the 91 005 
participants eligible for the analysis of breast cancer risk, 30 912 
were excluded from the analysis of proliferative BBD because they 
reported a prior history of BBD (n = 29 496) on the 1989 or 1991 
questionnaires, died or developed cancer before 1991 (n = 261), their 
biopsy date was before the return date of the 1991 questionnaire 
(n = 40), or their parity was missing in 1991 (n = 1115). Therefore, 
60 093 women were included in the analysis of proliferative BBD.
Breast Cancer Cases
Incident breast cancer cases were ascertained on biennial follow-
up questionnaires or by a search of the National Death Index. For 
self-reported breast cancer cases, permission to review medical 
records was requested. A review of pathology reports, which were 
obtained for 92% of the self-reported diagnoses, confirmed 99% of 
self-reported breast cancers (21). Carcinoma in situ was excluded 
from the analysis. Estrogen receptor (ER) and progesterone recep-
tor (PR) status were abstracted from pathology reports.
Biopsy-Confirmed Proliferative BBD
Slides from benign breast biopsies were reviewed by one of three 
pathologists (L. C. Collins, S. J. Schnitt, J. L. Connolly) who were 
blinded to participants’ exposures. BBD was classified according to 
the criteria of Dupont and Page (22) into one of three categories: 
nonproliferative, proliferative without atypia, and atypical hyperpla-
sia. Among 3273 participants reporting a first diagnosis of biopsy-
confirmed BBD on the 1993 to 2001 questionnaires, breast biopsy 
specimens were reviewed for 2120 women, and 2056 BBD cases 
were confirmed (20). Given that proliferative BBD is an established 
predictor of breast cancer, the analysis of BBD risk was restricted to 
1348 proliferative BBD cases with or without atypia (20).
Statistical Analyses
For the analysis of breast cancer risk, participants contributed 
person-time from the return date of the 1989 questionnaire until 
the date of diagnosis, date of death, date of drop-out, date of self-
reported cancer other than nonmelanoma skin cancer, or June 
2009, whichever came first. Women who developed any type of 
cancer (except nonmelanoma skin cancer) were censored at the 
time of their diagnosis. We used Cox proportional hazards models 
to compute relative risks (RRs) and 95% confidence intervals 
(CIs). Assumptions of proportionality for Cox models were 
confirmed based on scaled Schoenfeld residuals. The models were 
controlled for established risk factors of breast cancer, including 
age (continuous), questionnaire year (continuous), current body 
mass index (quintiles), age at menarche (<12, 12, 13, or ≥14 years), 
menopausal status (premenopausal, postmenopausal, or unknown), 
average body size between ages 5 and 10  years (somatotype 
pictogram 1, 1.5–2, 2.5–3, 3.5–4.5, ≥5, or unknown), family history 
of breast cancer in mother or sister(s) (yes or no), postmenopausal 
hormone use (never use, ever use, or unknown), total duration of 
breastfeeding (0, 0.1–11  months, ≥12  months, or unknown), and 
parity and age at first pregnancy (nulliparous; 1–2 pregnancies, 
age at first pregnancy <25  years; 1–2 pregnancies, age at first 
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pregnancy 25–29  years; 1–2 pregnancies, age at first pregnancy 
≥30  years; ≥3 pregnancies, age at first pregnancy <25  years; ≥3 
pregnancies, age at first pregnancy 25–29 years; ≥3 pregnancies, age 
at first pregnancy ≥30 years, or unknown). Age, body mass index, 
menopausal status, postmenopausal hormone use, total duration 
of breastfeeding, parity, and age at first pregnancy were updated 
in each questionnaire cycle. Family history of breast cancer was 
initially asked on the 1989 questionnaire and was updated in 1997. 
We also stratified the analysis of cumulative drinking before first 
pregnancy by the median menarche to first pregnancy interval.
Participants contributed person-time to the analysis of BBD 
from the return date of the 1991 questionnaire until the date of 
diagnosis, date of death, date of drop-out, date of self-reported can-
cer other than nonmelanoma skin cancer, or June 2001, whichever 
came first. The multivariable analyses were adjusted for the covari-
ables as described above.
Tests for trend were performed by using alcohol consumption as 
a continuous variable in the multivariable model. Interactions were 
assessed by entering cross-product terms in multivariable-adjusted 
models. The statistical significance of an interaction term was evalu-
ated by using the likelihood ratio test. Because two alcohol con-
sumption variables were assessed in the same cohort of women, we 
computed Wald statistics to compare cumulative drinking before first 
pregnancy with after first pregnancy regarding their relative risks of 
breast cancer and proliferative BBD. To determine whether alcohol 
intake before first pregnancy is differentially associated with hormone 
receptor–defined tumor subtypes, the Cox proportional hazards 
model was used with different subtypes treated as competing risks 
(23). Specifically, we estimated the relative risks of tumor subtypes 
using the approach described by Lunn and McNeil (24) and com-
puted the Wald statistic to test for heterogeneity. We did not stratify 
all analyses by race/ethnicity because 96% of the participants were 
white. All statistical analyses were performed by SAS (version 9.1; 
SAS Institute, Cary, NC). P values less than or equal to .05 were con-
sidered statistically significant, and all statistical tests were two-sided.
results
Among 91 005 women eligible for the analysis of breast cancer risk, 
20.4% did not drink alcohol between menarche and first pregnancy, 
and 3.8% reported moderate to high alcohol consumption (≥15 g/
day). Compared with nondrinkers, women who drank alcohol 
between menarche and first pregnancy were younger (Table  1). 
After adjustment for age, drinkers reported an older age at first 
pregnancy and were more likely to have a first-degree family 
history of breast cancer. Cumulative average alcohol consumption 
between menarche and first pregnancy was moderately correlated 
with both current drinking at baseline (Pearson correlation 
coefficient r  =  0.32; P < .001) and cumulative average drinking 
since first pregnancy (r = 0.59; P < .001).
Breast Cancer
We identified 1609 breast cancer cases between 1989 and 2009. 
Cumulative average alcohol consumption between menarche 
and first pregnancy was associated with increased risk for breast 
cancer (RR  =  1.13 per 10 g/day [approximately 6 drinks/week] 
intake; 95% CI  =  1.03 to 1.24) as was alcohol intake after first 
pregnancy (RR = 1.11 per 10 g/day intake; 95% CI = 0.99 to 1.24) 
(Table 2). Age-adjusted incidence rates were 197 cases per 100 000 
person-years among women who had at least 15 g/day alcohol 
intake before first pregnancy and 144 cases per 100 000 person-
years among nondrinkers before first pregnancy. Age-adjusted 
Table 1. Characteristics* of parous women (n = 91 005) aged 25 to 44 years in 1989, according to cumulative average alcohol consumption 
between menarche and first full-term pregnancy†, Nurses’ Health Study II
Characteristic
Cumulative average alcohol intake, g/day
0 0.1–4.9 5.0–14.9 ≥15.0
No. of participants 18 555 50 513 18 485 3452
Age at baseline, mean (SD), y 35.5 (4.6) 34.5 (4.7) 33.2 (4.5) 32.7 (4.5)
Age at menarche, mean (SD), y 12.3 (1.4) 12.4 (1.4) 12.5 (1.4) 12.5 (1.5)
Body mass index at baseline, mean (SD), kg/m2 24.3 (5.1) 23.9 (4.7) 23.8 (4.6) 24.6 (5.3)
Average body size between ages 5 and 10 y‡, mean (SD) 2.5 (1.2) 2.6 (1.2) 2.6 (1.2) 2.7 (1.3)
Premenopausal at baseline, % 97 98 98 97
Family history of breast cancer in mother or sister(s)  
at baseline, %
5 6 6 7
Current alcohol intake at baseline, mean (SD), g/day 0.8 (3.4) 2.3 (4.4) 5.1 (6.9) 8.5 (13.7)
No. of full-term pregnancies, mean (SD) 2.4 (1.0) 2.3 (0.9) 2.2 (0.9) 2.2 (0.9)
Age at first full-term pregnancy, mean (SD), y 24.5 (4.6) 26.8 (4.5) 27.6 (4.8) 27.8 (5.0)
Interval between menarche and first full-term  
pregnancy, mean (SD), y
9.4 (4.6) 11.8 (4.5) 12.5 (4.8) 12.7 (5.0)
Total duration of breastfeeding, %
 None 22 24 25 27
 0.1–11 months 36 35 33 31
 ≥12 months 25 27 29 29
 Missing 17 14 13 14
Cumulative alcohol intake after first pregnancy at base-
line, mean (SD), g/day
0.6 (2.3) 2.2 (3.1) 6.1 (5.7) 13.1 (11.7)
* All variables except for age are age-standardized. SD = standard deviation.
† Full-term pregnancy was defined as a pregnancy achieving at least 6 months of gestation.
‡ Childhood body size was estimated by averaging each participant’s somatograms (1–9 scale) at ages 5 and 10 (25).
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incidence rates were 195 cases per 100 000 person-years for at 
least 15-g/day alcohol intake after first pregnancy and 138 cases 
per 100 000 person-years for non drinking after first pregnancy. 
The relative risk for cumulative drinking between menarche and 
first pregnancy remained statistically significant after additional 
adjustment for drinking after first pregnancy (RR = 1.11 per 10g/
day intake; 95% CI = 1.00 to 1.23; Ptrend = .051); the relative risk 
was 1.34 (95% CI = 1.00 to 1.80; P = .051) for those with alcohol 
intake of at least 15 grams per day (approximately 1.3 drinks/day) 
compared with nondrinkers. Additional adjustment for cumula-
tive drinking before first pregnancy slightly attenuated the RR for 
alcohol intake after first pregnancy to 1.09 (95% CI = 0.96 to 1.23) 
per 10 g/day drinking; the RR was 1.21 (95% CI = 0.84 to 1.76) 
for daily alcohol intake of at least 15 grams after first pregnancy 
as compared with nondrinkers. The results remained unchanged 
when the analysis was further adjusted for oral contraceptive use 
or limited to premenopausal women.
We further analyzed the association between cumulative aver-
age alcohol consumption before first pregnancy and breast cancer 
risk according to the length of the menarche to first pregnancy 
interval (Table 3; Figure 1). The risk estimates for alcohol intake 
before first pregnancy were stronger among women with 10 years 
or more between these two reproductive events as compared with 
women with a duration of less than 10 years (Pinteraction = .01). A 10-g 
increase in cumulative daily alcohol consumption before first preg-
nancy was associated with a relative risk of 1.21 (95% CI = 1.08 
to 1.36) among women with a duration of 10 years or more. We 
further subdivided this group and observed that the relative risk per 
10 g/day drinking was 1.14 (95% CI = 0.97 to 1.34) among women 
with a duration between 10 and 14 years and 1.25 (95% CI = 1.06 
to 1.48) among women with a duration of 15 years or more.
To explore if BBD is in the causal pathway between drinking 
before first pregnancy and breast cancer, we adjusted the multivari-
able model for self-reported BBD, and the relative risk for drink-
ing before first pregnancy was attenuated to 1.07 (95% CI = 0.96 
to 1.20) per 10 g/day intake. Among BBD cases (n = 18 473), per 
10 g/day drinking before first pregnancy was associated with a 13% 
(RR = 1.13; 95% CI = 0.94 to 1.37) increase in risk.
We also analyzed the risks associated with cumulative drinking 
between menarche and first pregnancy by ER/PR status (Table 4). 
Cumulative drinking before first pregnancy tended to be more 
strongly related to risks of ER+/PR+ tumors (RR = 1.18 per 10 g/
day intake; 95% CI  =  1.03 to 1.34) compared with the risks for 
ER+/PR− tumors (RR = 0.86; 95% CI = 0.60 to 1.22) and ER−/PR− 
tumors (RR = 0.84; 95% CI = 0.60 to 1.16; Pheterogeneity = .06).
Proliferative BBD
A total of 970 proliferative BBD cases were diagnosed between 
1991 and 2001 and confirmed by central histology review. An 
increasing trend in the risk of proliferative BBD was observed 
with a 10-g increase in cumulative alcohol consumed between 
menarche and first pregnancy after adjustment for cumulative 
drinking after first pregnancy (RR = 1.16; 95% CI = 1.02 to 1.32; 
298 cases per 100 000 person-years for at least 15 g/day intake 
and 271 cases per 100 000 person-years for nondrinkers), which 
appeared to be stronger than the risk for cumulative drinking 
after first pregnancy (Pheterogeneity = 0.08) (Table 2). The association 
between alcohol consumption before first pregnancy and prolifera-
tive BBD appeared to be restricted to women with longer durations 
between menarche and first pregnancy. Among women with less 
than 10 years between menarche and first pregnancy, the relative 
risk per 10 g/day drinking was 1.06 (95% CI = 0.85 to 1.31); among 
women with duration of 10 or more years the relative risk was 1.20 
(95% CI = 1.03 to 1.40) (Table 3; Figure 1). This pattern is similar 
to what was observed with breast cancer, although the difference 
by duration between menarche and first pregnancy was not statisti-
cally significant for proliferative BBD.
Discussion
In this prospective analysis, we observed that alcohol intake before 
first pregnancy was consistently associated with increased risks of 
proliferative BBD and breast cancer, independent of drinking after 
first pregnancy. Such associations tended to be stronger among 
women with 10 or more years between menarche and first preg-
nancy. These findings add support to the importance of exposure 
between menarche and first pregnancy in breast cancer develop-
ment (18).
Given the susceptibility of the undifferentiated nulliparous 
breast tissue to carcinogenic insults, alcohol consumed between 
menarche and first pregnancy may have a greater adverse effect. 
A small number of epidemiological studies have addressed the tim-
ing of alcohol consumption in relation to breast cancer risk, with 
the majority reporting no association with drinking in early life (5–
7,9,11). However, the timing of alcohol consumption was evaluated 
only in terms of chronological age in these studies, mixing exposure 
before and after first pregnancy. In a prospective analysis of the 
NHS data, Chen et al. (2) used chronological age cutoffs and com-
pared cumulative drinking between ages 18 and 40 years and after 
age 40 years with breast cancer risk, observing statistically signifi-
cant associations of similar magnitude (RR = 1.07–1.08 per 10 g/
day consumption) for drinking in early and late life. In that analysis, 
drinking before first pregnancy was not explicitly addressed. Using 
the NHSII data, we refined the approach to specifically address 
how alcohol intake before first pregnancy affects risks of prolifera-
tive BBD and breast cancer.
We observed that cumulative alcohol consumption before, 
rather than after, first pregnancy was associated with elevated inci-
dence of proliferative BBD. This finding is consistent with previous 
analyses in this cohort that drinking between ages 18 and 22 years is 
associated with increased risk of proliferative BBD (19,20). Among 
their daughters, drinking between ages 16 and 22 years was associ-
ated with increased risk of biopsy-confirmed BBD (odds ratio = 1.50 
per drink per day; 95% CI = 1.19 to 1.90) (27). However, drinking 
in the past year was not related to risk of proliferative BBD in two 
case–control studies (28,29) and a prospective study among post-
menopausal women (30). These results suggest that drinking early 
in life may have a greater adverse effect on risk of proliferative BBD 
compared with drinking later in life. Given that proliferative BBD 
is a well-confirmed risk marker for breast cancer, the association 
observed between drinking early in life and breast cancer may be, in 
part, mediated through proliferative BBD. In our study, additional 
adjustment for BBD reduced the relative risk of breast cancer for 
drinking before first pregnancy; drinking before first pregnancy was 
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related to a non-statistically significant increase in risk among BBD 
cases. This indicates that BBD may be a pathway linking drinking in 
early life and breast cancer but not the only route.
The longer the duration of menarche to first pregnancy, the 
higher is a woman’s risk of breast cancer (14,15,17). Compared 
with nondrinkers with a shorter duration, nondrinkers with dura-
tion of 10 or more years between menarche and first pregnancy 
had 26% and 81% increased risk of breast cancer and proliferative 
BBD in our analysis, respectively. Pregnancy induces decreases in 
the number of hormone-sensitive luminal cells and downregulation 
of the Wnt signaling pathway in basal stem/progenitor cells, mak-
ing breast tissue less susceptible to carcinogens (31). Additionally, 
first pregnancy induces long-term hormonal changes, including 
reduced prolactin and estrogen and increased sex hormone–bind-
ing globulin, which may provide further protection against breast 
cancer (32,33). Importantly, we observed that alcohol drinking 
between menarche and first pregnancy conferred excess risk of 
breast cancer and of proliferative BBD among women who had 
first pregnancy 10 or more years after menarche.
The primary limitation of this analysis is the reliability of recalled 
drinking in the specific age periods. However, recalled drinking 
during adolescence is moderately reproducible (intraclass  cor-
relation coefficient = 0.50) and is largely independent of current 
(adult) alcohol intake (intraclass  correlation coefficient  =  0.14) 
in the NHSII participants (34). The prospective data collection 
and evaluation of incident disease avoids differential recall bias. 
Proliferative BBD is histologically divided into two groups, with 
atypia conferring higher risk of subsequent breast cancer than 
hyperplasia without atypia (35–38). However, the small number of 
cases with atypia limited our ability to examine this subgroup.
Population attributable risk estimates (39) showed that 4% 
of breast cancer cases and 11% of proliferative BBD cases were 
attributable to drinking before first pregnancy. It is estimated that 
232 340 breast cancer cases will be diagnosed in 2013 (40). Thus, 
approximately 11 617 breast cancer cases would not occur if the 
persons at risk did not drink alcohol before their first pregnancy.
In conclusion, this prospective study provides evidence that 
alcohol consumption before first pregnancy was dose-dependently 
associated with increased risk of both proliferative BBD and breast 
cancer, independent of drinking after first pregnancy. This increase 
in risk tended to be more pronounced among women with a longer 
time interval between menarche and first pregnancy compared 
with women with a shorter interval, consistent with breast cancer 
risk models (13–15). The general consistency in the patterns of 
association between alcohol and risk of proliferative BBD and of 
breast cancer lends support to the hypothesis that alcohol intake, 
particularly before first pregnancy when breast tissue is likely at its 
most vulnerable stage, may play an important role in the etiology 
of breast cancer. Reducing alcohol consumption during this period 
may be an effective prevention strategy for breast cancer.
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